Retatrutide (also known as LY3437943) is an advanced triple incretin receptor agonist that simultaneously targets the glucose-dependent insulinotropic polypeptide (GIP) receptor, glucagon-like peptide-1 (GLP-1) receptor, and glucagon receptor. This triple-receptor mechanism distinguishes it from dual agonists such as tirzepatide, offering researchers an additional lever of metabolic modulation through glucagon receptor activation, which plays a key role in hepatic glucose output and energy expenditure.
In preclinical and early clinical research, retatrutide has demonstrated substantial effects on body weight reduction, insulin sensitivity, and lipid metabolism, making it a highly relevant compound for obesity, type 2 diabetes, and non-alcoholic fatty liver disease (NAFLD/NASH) research programmes. Its glucagon component may also support investigations into energy homeostasis and thermogenesis.
Each vial contains 25mg of retatrutide as a lyophilised powder with a purity of >98% as verified by HPLC and mass spectrometry. Molecular formula: C₂₂₄H₃₅₂N₅₈O₇₀S. Molecular weight: approximately 4963.5 g/mol. CAS number: 2381089-83-2.
Store at -20°C in a dry environment, protected from light. Once reconstituted, use within 28 days when stored at 4°C.
Molecular Formula
C₂₂₄H₃₅₂N₅₈O₇₀S
Molecular Weight
4963.5 g/mol
Purity
>98%
CAS Number
2381089-83-2
Form
Lyophilised Powder
Research Applications
Obesity and body weight regulation, Type 2 diabetes and insulin resistance, Non-alcoholic fatty liver disease (NAFLD/NASH), Lipid metabolism and dyslipidaemia, Energy homeostasis and thermogenesis, Incretin receptor pharmacology
For research purposes only. Not for human use.
Reviews
There are no reviews yet.